Content about Regeneron

January 13, 2014

A drug maker has started a program to find the genetic determinants of human disease and speed the discovery and development of new drugs. The program includes a five-year project that it said would be one of the largest of its kind in terms of the number of patients involved.

TARRYTOWN, N.Y. — A drug maker has started a program to find the genetic determinants of human disease and speed the discovery and development of new drugs. The program includes a five-year project that it said would be one of the largest of its kind in terms of the number of patients involved.

November 15, 2013

New cardiovascular health guidelines released this week could dampen the potential popularity of an up-and-coming class of cholesterol drugs, according to published reports.

NEW YORK — New cardiovascular health guidelines released this week could dampen the potential popularity of an up-and-coming class of cholesterol drugs, according to published reports.

September 24, 2012

The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

TARRYTOWN, N.Y. — The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

Regeneron Pharmaceuticals announced the approval of Eylea (aflibercept) for treating macular edema following central retinal vein occlusion, or CRVO. Eylea already was approved for treating neovascular age-related macular degeneration, another eye disease.

January 19, 2012

The wholesale arm of specialty pharmacy The Apothecary Shops has received distribution rights to a drug for treating age-related macular degeneration, the company said Thursday.

PHOENIX — The wholesale arm of specialty pharmacy The Apothecary Shops has received distribution rights to a drug for treating age-related macular degeneration, the company said Thursday.

Apothecary Shops Wholesale has begun distributing Regeneron Pharmaceuticals' Eylea (aflibercept) to physicians and patients. The drug is used to treat neovascular or "wet" AMD. The "wet" form usually leads to more serious vision loss.

November 28, 2011

Bayer HealthCare and Regeneron Pharmaceuticals have started a late-stage clinical trial in China to evaluate a drug for eye disorders, the companies said Monday.

TARRYTOWN, N.Y. — Bayer HealthCare and Regeneron Pharmaceuticals have started a late-stage clinical trial in China to evaluate a drug for eye disorders, the companies said Monday.

The drug makers announced the start of the phase-3 "SIGHT" trial of Eylea (aflibercept) injection for the treatment of the neovascular form of age-related macular degeneration, also known as wet AMD. The companies said the trial, which will include about 300 patients, will be the largest retinal trial conducted in China.

June 20, 2011

A panel of Food and Drug Administration experts has recommended approval of an investigational biotech drug made by Regeneron Pharmaceuticals for eye diseases.

TARRYTOWN, N.Y. — A panel of Food and Drug Administration experts has recommended approval of an investigational biotech drug made by Regeneron Pharmaceuticals for eye diseases.

Regeneron said Friday that the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee unanimously recommended approval of Eylea (aflibercept) ophthalmic solution for the treatment of a form of age-related macular degeneration, also known as wet AMD. The disease causes abnormal growth of new blood vessels in the eye.

April 8, 2011

Regeneron and Bayer HealthCare have initiated 1-of-2 late-stage clinical trials of their aflibercept ophthalmic solution in the treatment of a complication caused by diabetic retinopathy.

TARRYTOWN, N.Y. and BERLIN — Regeneron and Bayer HealthCare have initiated 1-of-2 late-stage clinical trials of their aflibercept ophthalmic solution in the treatment of a complication caused by diabetic retinopathy.

The drug makers said that it would evaluate the efficacy of VEGF Trap-Eye (aflibercept ophthalmic solution) in the treatment of diabetic macular edema, a prevalent cause of vision loss among diabetes patients, after promising results from its previous clinical trial.

March 11, 2011

While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.

TARRYTOWN, N.Y. — While failing to improve overall survival, an investigational treatment for non-small cell lung cancer made by Sanofi-Aventis and Regeneron Pharmaceuticals did keep the disease from worsening and, overall, caused patients to respond to treatment, according to results of a late-stage clinical trial.

Sanofi and Regeneron announced Thursday results of the phase-3 “VITAL” trial of aflibercept. Patients were administered either the drug or placebo in addition to docetaxel chemotherapy.